stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) EPS (diluted)
Arrowhead Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was −$0.01, compared with −$5.00 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.25. Over the past ten years it has ranged from −$5.00 (fiscal 2024) to $0.69 (fiscal 2019); the current reading is higher than 91% of that period. Arrowhead Pharmaceuticals, Inc. ranks 337th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.01 | — |
| FY2024 | −$5.00 | — |
| FY2023 | −$1.92 | — |
| FY2022 | −$1.67 | — |
| FY2021 | −$1.36 | — |
| FY2020 | −$0.84 | — |
| FY2019 | $0.69 | — |
| FY2018 | −$0.65 | — |
| FY2017 | −$0.47 | — |
| FY2016 | −$1.34 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.36 | — |
| Mar 2026 | −$0.93 | — |
| Dec 2025 | $0.22 | — |
| Sep 2025 | −$0.18 | — |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| CORT Corcept Therapeutics Incorporated compare | $1.29 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| ARWR Arrowhead Pharmaceuticals, Inc. | −$2.25 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ARWR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement